Celltrion's Omriclo Fully Launched in Major European Countries... Accelerates Market Expansion

Expanding Direct Sales Presence Across Europe
Accelerating Market Share Growth Through Competitive Advantage

Celltrion announced on the 25th that Omriclo (ingredient: omalizumab, 75mg/150mg), its treatment for chronic idiopathic urticaria launched in Europe last September, has now been released in major countries including Germany, Spain, the United Kingdom, and France.

Omriclo, a treatment for chronic idiopathic urticaria. Celltrion

Omriclo became the first omalizumab biosimilar to receive approval from the European Medicines Agency (EMA) in May last year. Celltrion began its European rollout as a first mover, starting with Norway, a key Northern European market, and expects to gain a competitive edge through early market entry.

In fact, Celltrion succeeded in securing early market share in the Netherlands, where the EMA headquarters is located, by winning bids immediately upon launch. Celltrion's Dutch subsidiary has secured contracts with multiple hospital groups and plans to supply Omriclo sequentially. The volume awarded in this round of bidding accounts for approximately 70% of the entire omalizumab market in the Netherlands.

Celltrion plans to continue expanding the number of European countries where Omriclo is available, while implementing customized direct sales strategies tailored to each country's market environment to maximize its first-mover advantage. In countries such as Spain and the United Kingdom, where bidding is central to the market, Celltrion aims to leverage the absence of competing biosimilar products to secure a bidding advantage. In sales-driven markets such as Germany, the company will focus on targeted marketing activities for key supply channels, including healthcare professionals and pharmacies, to raise Omriclo's brand awareness.

Ha Taehoon, Head of Celltrion Europe, stated, "Omriclo is the first omalizumab biosimilar to be launched in the European market, and we are expanding our market influence based on data on quality, efficacy, and safety. Building on the trust Celltrion has established in Europe through our direct sales system, we will continue to expand the number of countries where Omriclo is available so that more patients can access treatment, further solidifying our position in the European market."

Meanwhile, Omriclo, developed by Celltrion, is used for the treatment of chronic idiopathic urticaria and asthma. The original drug, Xolair, recorded global sales of approximately 6.4992 trillion won last year.

This content was produced with the assistance of AI translation services.